Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.09 USD

113.09
11,127,844

-1.64 (-1.43%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Company News For May 22, 2019

Companies In The News Are: KSS,AZO,HD,MRK

Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

Merck's Keytruda Fails in Late-Stage Breast Cancer Study

Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

AbbVie's Brain Cancer Candidate Fails in Phase III Study

AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

Nalak Das headshot

4 Dow Stocks to Buy on the Dip Despite Market Volatility

After an impressive bull run in the first four months of this year, it seems volatility is once again ready to rear its ugly face in Wall Street.

Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

What's in Store for Affimed (AFMD) This Earnings Season?

Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.

Endo (ENDP) Q1 Earnings & Revenues Beat Estimates

Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.

Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates

Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.

Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates

Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Merck, Charter Communications, Anthem and Norfolk Southern

The Zacks Analyst Blog Highlights: Berkshire Hathaway, Merck, Charter Communications, Anthem and Norfolk Southern

Mark Vickery headshot

Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Merck (MRK) and Charter Communications (CHTR).

ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

Swarup Gupta headshot

Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress

The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.

Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.